Rheumatology Advance Access published online on September 1, 2007
Rheumatology, doi:10.1093/rheumatology/kem208
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
A case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy—response
Department of Rheumatology, Harrogate Health Care NHS Trust, Lancaster Park Road, Harrogate HG2 7SX, UK
Correspondence to:
Dr Mike Green, Consultant Rheumatologist, Harrogate Health Care NHS Trust, Lancaster Park Road, Harrogate HG2 7SX, UK. E-mail: mike.green@hdft.nhs.uk
| The first 10% of the full text of this article appears below. |
SIR, We wish to respond to the recent case report of a patient with mixed connective tissue disease whose Raynaud's phenomenon responded to Rituximab therapy [1]. We would like to report a patient with undifferentiated, anti-nuclear antibody (ANA)-positive, connective tissue disease whose Raynaud's phenomenon did not respond to Rituximab.
A 32-yr-old woman presented in 2004 with severe triphasic Raynaud's, livedo, large joint arthralgia and a strongly positive ANA (nucleolar staining, 1: 1600 titre). She